The Cardiovascular Effects of Semaglutide
An international consortium of researchers has determined that oral semaglutide lessens the danger of adverse outcomes in individuals dealing with heart failure. This therapeutic benefit is particularly pronounced amongst those diagnosed with type 2 diabetes.
Clinical Investigation
The trial took place across 444 medical centers situated in 33 nations, involving 9,650 participants whose average age was 66 years. The experimental phase spanned approximately four years. For patients retaining a normal heart ejection fraction, semaglutide reduced the probability of cardiovascular complications, whereas in subjects with a reduced ejection fraction, the drug exhibited no discernible effect.
Contraindications and Advisory Notes
Semaglutide proves successful in averting complications for individuals with type 2 diabetes. Medical professionals strongly emphasize that the medication must only be administered under professional medical supervision. Self-administration without a specialist’s prescription poses potential health risks.
The Need for Further Inquiry
To gain a more precise comprehension of semaglutide’s efficacy across different left ventricular ejection fraction levels, supplementary clinical studies will be essential. The findings from this current investigation have been featured in the publication JAMA Internal Medicine.
About the Author
